Expert forum
首頁(yè) 專(zhuān)家論壇 標(biāo)本專(zhuān)家A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers
登錄注冊(cè)
A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers
2017-12-08 07:37來(lái)源:原版作者:Hristozova T
Circulating tumor cells (CTCs) might not only serve as prognostic marker but could also be useful for monitoring treatment efficacy. A multicolor flow cytometry protocol for their detection and molecular characterization in peripheral blood was developed which consisted of erythrocyte lysis followed by staining of cells with fluorochrome-labeled antibodies against CD45 and the epithelial markers EpCam and cytokeratin 7/8. For reducing the number of events acquired by flow cytometry, an electronic threshold for the fluorescent signals from the epithelial markers was applied. After establishment of the protocol by using spiking experiments, its suitability to determine the absolute number of CTCs as well as their expression of epidermal growth factor receptor (EGFR) and its phosphorylated form (phospho-EGFR) in blood samples from patients with squamous cell carcinoma of the head and neck (SCCHN) was validated. Spiking experiments demonstrated an excellent recovery (mean 85%) and a linear performance (R(2) = 0.98) of the protocol. Sensitivity and specificity were comparable to our former protocol using immunomagnetic CTC pre-enrichment. The analysis of 33 SCCHN patient samples revealed the presence of CTCs in 33.3% of cases with a mean ± SD of 1.5 ± 0.5 CTCs per 3.75 ml blood. EGFR was expressed in 100% and phospho-EGFR in 36.4% of the CTC+ cases. We have established a simple and sensitive multicolor flow cytometry protocol for detection of CTCs in patients with epithelial cancers including SCCHN which will allow their detailed molecular characterization.
版權(quán)聲明:
本網(wǎng)站所有注明“來(lái)源:“陽(yáng)普醫(yī)療”的文字、圖片和音視頻資料,版權(quán)均屬于陽(yáng)普醫(yī)療所有,非經(jīng)授權(quán),任何媒體、網(wǎng)站或個(gè)人不得轉(zhuǎn)載,授權(quán)轉(zhuǎn)載時(shí)須注明
“來(lái)源:陽(yáng)普醫(yī)療”。本網(wǎng)所有轉(zhuǎn)載文章系出于傳遞更多信息之目的,且明確注明來(lái)源和作者,不希望被轉(zhuǎn)載的媒體或個(gè)人可與我們聯(lián)系,我們將立即進(jìn)行刪除處理。
下一篇:Multicolor detection of rare tumor cells in blood using a novel flow cytometry-based system.
返回首頁(yè)網(wǎng)友評(píng)論:
版主信息
昵稱(chēng):Mandy Luo
郵箱:mandyluo@improve-medical.com
相關(guān)閱讀
- > 《醫(yī)學(xué)拾萃》2023年12月刊:簡(jiǎn)述實(shí)驗(yàn)室信息管理系統(tǒng)發(fā)展歷程
- > 《醫(yī)學(xué)拾萃》2023年10月刊:分析前標(biāo)本處理對(duì)神經(jīng)元特異性烯醇化酶(NSE)檢測(cè)的影響
- > 《醫(yī)學(xué)拾萃》2023年8月刊:PSA 檢測(cè)的標(biāo)本處理、質(zhì)量控制及其臨床應(yīng)用
- > 《醫(yī)學(xué)拾萃》2023年6月刊:真空采血管標(biāo)本放置時(shí)間和溫度對(duì)常見(jiàn)檢驗(yàn)項(xiàng)目的影響
- > 《醫(yī)學(xué)拾萃》2023年4月刊:游離 DNA 管使用現(xiàn)狀與展望
- > 《醫(yī)學(xué)拾萃》2023年2月刊:肝素管的臨床適用檢測(cè)項(xiàng)目與不適用項(xiàng)
- > 《醫(yī)學(xué)拾萃》2022年12月刊:血清分離技術(shù)及其對(duì)臨床生化檢驗(yàn)結(jié)果的影響
- > 《醫(yī)學(xué)拾萃》2022年10月刊:標(biāo)本處理對(duì)心肌肌鈣蛋白測(cè)定的影響
- > 《醫(yī)學(xué)拾萃》2022年8月刊:一種新型材料-水凝膠的合成及其應(yīng)用
- > 《醫(yī)學(xué)拾萃》2022年6月刊:RFID 技術(shù)及其在醫(yī)療和標(biāo)本管理中的應(yīng)用與發(fā)展